Log in
Imidazole antifungal

Ketoconazole

Ketoconazole is an imidazole antifungal agent that inhibits fungal ergosterol synthesis by blocking the cytochrome P450 enzyme 14α-demethylase. It is primarily used topically for dermatophyte and yeast infections, while systemic use has been largely replaced by newer azoles due to significant hepatotoxicity. The most testable fact is that ketoconazole potently inhibits CYP3A4 and causes severe drug interactions.

Practice questionsHigh-yield facts
Drug classImidazole antifungal
MechanismInhibits fungal 14α-demethylase blocking ergosterol synthesis
Main usesTopical fungal infections seborrheic dermatitis tinea
Key adverse effectHepatotoxicity and CYP3A4 inhibition causing drug interactions
5 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Ketoconazole inhibits the fungal cytochrome P450 enzyme 14α-demethylase (CYP51A1), which is essential for converting lanosterol to ergosterol. Ergosterol is a critical component of fungal cell membranes, analogous to cholesterol in mammalian cells. By blocking ergosterol synthesis, ketoconazole disrupts fungal membrane integrity, increases permeability, and inhibits fungal growth.

At higher concentrations, ketoconazole is fungicidal. The drug is selective for fungal CYP450 enzymes but also inhibits mammalian CYP450 isoenzymes, particularly CYP3A4, which accounts for many of its drug interactions and adverse effects. Ketoconazole also inhibits steroidogenesis by blocking 17α-hydroxylase and 11β-hydroxylase, leading to decreased cortisol and testosterone synthesis at systemic doses.

High-yield for exams
  • Ketoconazole inhibits fungal 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity
  • Potent CYP3A4 inhibitor causing dangerous interactions with statins, ergots, immunosuppressants, and QT-prolonging drugs
  • Systemic ketoconazole carries a black box warning for hepatotoxicity and requires liver function monitoring
  • Inhibits adrenal steroidogenesis (17α-hydroxylase, 11β-hydroxylase), reducing cortisol and testosterone
  • Oral absorption requires gastric acidity; reduced by PPIs, H2-blockers, and antacids
  • Topical formulations widely used for tinea infections, seborrheic dermatitis, and dandruff with minimal systemic effects
  • Can cause gynecomastia, menstrual irregularities, and adrenal insufficiency due to hormone synthesis inhibition
  • Largely replaced by safer azoles (fluconazole, itraconazole) for systemic fungal infections due to toxicity profile

Indications

Topical ketoconazole is used for:

  • Dermatophyte infections including tinea corporis, tinea cruris, tinea pedis, and tinea versicolor
  • Seborrheic dermatitis of the scalp and body
  • Cutaneous candidiasis
  • Dandruff (over-the-counter shampoo formulations)

Systemic ketoconazole use has been restricted due to hepatotoxicity. In some jurisdictions, oral ketoconazole is reserved for:

  • Cushing syndrome (off-label) when other treatments have failed, exploiting its adrenal steroidogenesis inhibition
  • Severe endemic fungal infections only when alternative azoles are unavailable or ineffective

Systemic ketoconazole has been largely replaced by fluconazole, itraconazole, voriconazole, and posaconazole for invasive fungal infections. Topical formulations remain widely used and well-tolerated.

Pharmacokinetics

Absorption: Oral ketoconazole requires an acidic gastric environment for dissolution and absorption. Bioavailability is reduced by antacids, H2-blockers, and proton pump inhibitors. Peak plasma concentrations occur 1-2 hours after oral administration. Topical ketoconazole has minimal systemic absorption.

Distribution: Ketoconazole is highly protein-bound (99%) and distributes well into tissues including skin, nails, and sebum. It penetrates poorly into cerebrospinal fluid, limiting its use for CNS fungal infections.

Metabolism: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Ketoconazole is both a substrate and a potent inhibitor of CYP3A4, leading to auto-inhibition and nonlinear pharmacokinetics.

Elimination: Primarily excreted in feces via bile; less than 13% is excreted unchanged in urine. The elimination half-life is approximately 8 hours after a single dose but increases with multiple dosing.

Adverse effects

Hepatotoxicity is the most serious adverse effect of systemic ketoconazole, occurring in approximately 1 in 10,000 patients. It can range from asymptomatic transaminase elevation to fulminant hepatic failure. Liver enzyme monitoring is required during systemic therapy. Hepatotoxicity is rare with topical use.

Endocrine effects result from steroidogenesis inhibition:

  • Gynecomastia and decreased libido (reduced testosterone)
  • Adrenal insufficiency (reduced cortisol, especially with high doses)
  • Menstrual irregularities

Gastrointestinal effects include nausea, vomiting, abdominal pain, and diarrhea, especially with oral formulations.

Drug interactions are common due to potent CYP3A4 inhibition. Ketoconazole increases levels of many drugs metabolized by CYP3A4, including certain statins (simvastatin, lovastatin), immunosuppressants (cyclosporine, tacrolimus), anticoagulants (warfarin), and benzodiazepines (midazolam, triazolam).

Topical formulations are generally well-tolerated. Local irritation, pruritus, or contact dermatitis may occur at application sites.

QT prolongation is a concern with systemic ketoconazole, particularly when co-administered with other QT-prolonging drugs.

Contraindications and warnings

Absolute contraindications for systemic ketoconazole:

  • Acute or chronic liver disease
  • Concomitant use with drugs that are CYP3A4 substrates and can prolong QT interval (e.g., cisapride, pimozide, quinidine, dofetilide)
  • Concomitant use with certain statins metabolized by CYP3A4 (simvastatin, lovastatin) due to rhabdomyolysis risk
  • Pregnancy (teratogenic in animal studies)

Black box warning (United States): Oral ketoconazole carries warnings for hepatotoxicity, QT prolongation, and drug interactions. It should only be used when alternative antifungal therapies are not available or tolerated.

Warnings:

  • Hepatic monitoring: Baseline and periodic liver function tests are required during systemic therapy. Discontinue if transaminases exceed 3 times the upper limit of normal or if clinical hepatitis develops.
  • Adrenal function: Monitor for adrenal insufficiency, particularly in patients receiving high doses or prolonged therapy.
  • Pregnancy category C: Avoid systemic use during pregnancy unless benefits outweigh risks.
  • Drug-induced gastric hypoacidity: Avoid concomitant antacids, H2-blockers, and proton pump inhibitors, which reduce ketoconazole absorption.

Topical ketoconazole is generally safe with minimal contraindications beyond hypersensitivity.

Drug interactions

Ketoconazole is a potent CYP3A4 inhibitor and causes numerous clinically significant drug interactions.

Drugs contraindicated with systemic ketoconazole:

  • Ergot alkaloids (ergotamine, dihydroergotamine): risk of ergotism
  • Certain statins (simvastatin, lovastatin): rhabdomyolysis risk
  • QT-prolonging drugs (cisapride, pimozide, quinidine, dofetilide): increased arrhythmia risk
  • Triazolam, oral midazolam: prolonged sedation
  • Lurasidone, ranolazine: excessive drug accumulation

Major interactions requiring dose adjustment or monitoring:

  • Immunosuppressants (cyclosporine, tacrolimus, sirolimus): increased levels, monitor drug concentrations
  • Anticoagulants (warfarin): enhanced anticoagulation, monitor INR closely
  • Calcium channel blockers: increased levels, monitor blood pressure
  • Corticosteroids: increased steroid levels, Cushing syndrome risk
  • Antiretrovirals (protease inhibitors, NNRTIs): bidirectional interactions
  • Oral hypoglycemics (sulfonylureas): increased risk of hypoglycemia

Drugs reducing ketoconazole absorption:

  • Proton pump inhibitors (omeprazole, lansoprazole)
  • H2-receptor antagonists (ranitidine, famotidine)
  • Antacids
  • Didanosine (contains buffering agents)

Rifampin induces CYP3A4 and significantly reduces ketoconazole levels, potentially causing treatment failure. Topical ketoconazole has minimal systemic drug interaction potential.

Clinical pearls

  • Ketoconazole shampoo is first-line for seborrheic dermatitis and dandruff, with efficacy comparable to topical corticosteroids and better safety.
  • Systemic ketoconazole is sometimes used off-label to treat refractory Cushing syndrome by inhibiting adrenal steroidogenesis, though this is not FDA-approved and requires close monitoring.
  • When oral ketoconazole is necessary, administer with acidic beverages (e.g., cola) or vitamin C to enhance absorption if the patient is on acid-suppressing therapy that cannot be discontinued.
  • The classic USMLE association is a patient on ketoconazole who develops hepatotoxicity or experiences a serious drug interaction with a CYP3A4 substrate.
  • Unlike fluconazole, ketoconazole penetrates poorly into CSF and is not suitable for CNS fungal infections such as cryptococcal meningitis.
  • Ketoconazole cream is effective for tinea versicolor (pityriasis versicolor) caused by Malassezia species.
  • Gynecomastia from ketoconazole results from inhibition of androgen synthesis enzymes (17α-hydroxylase, 17,20-lyase), leading to decreased testosterone and an altered testosterone-to-estrogen ratio.
  • Topical ketoconazole has anti-inflammatory properties beyond its antifungal effects, contributing to its efficacy in seborrheic dermatitis.
  • Always check for drug interactions before prescribing systemic ketoconazole due to its potent CYP3A4 inhibition—this is a common exam question scenario.
Mnemonic

KETO-CLASH: Ketoconazole's Effects Toxicity Overview - CYP3A4 inhibition, Liver toxicity, Adrenal suppression, Steroid synthesis blocked, Hormonal effects

Practice questions

1. A 45-year-old man with refractory Cushing syndrome is started on oral ketoconazole after unsuccessful transsphenoidal surgery. Two weeks later, he develops fatigue, nausea, and right upper quadrant discomfort. Laboratory studies show AST 420 U/L (normal 10-40) and ALT 390 U/L (normal 7-56). Which mechanism best explains this patient's hepatotoxicity?

Answer: A. Ketoconazole causes hepatotoxicity through direct mitochondrial injury from its metabolites, leading to hepatocellular damage with elevated transaminases. This is the most serious adverse effect of systemic ketoconazole and prompted a black box warning. Cholestatic patterns can occur but hepatocellular injury is more common. Cortisol suppression does not cause hepatic ischemia, and ketoconazole does not cause clinically significant immunosuppression that would reactivate viral hepatitis.

2. A 62-year-old man with atrial fibrillation on warfarin develops tinea pedis. His physician considers prescribing oral ketoconazole but decides against it. Instead, topical ketoconazole cream is recommended. Which property of systemic ketoconazole most likely influenced this decision?

Answer: C. Ketoconazole is a potent CYP3A4 inhibitor and also inhibits CYP2C9, the primary enzyme metabolizing S-warfarin (the more potent enantiomer). This inhibition increases warfarin levels, elevating INR and bleeding risk. Topical ketoconazole avoids systemic drug interactions. Ketoconazole does not induce CYP enzymes; it inhibits them. While protein displacement can occur, the sustained interaction is through metabolic inhibition, not transient displacement.

3. A 28-year-old woman with severe seborrheic dermatitis is prescribed ketoconazole 2% shampoo twice weekly. She is concerned about the same side effects her father experienced when he took oral ketoconazole for a fungal infection years ago, including liver problems and hormonal changes. What is the most appropriate response?

Answer: C. Topical ketoconazole formulations have minimal systemic absorption and do not cause the hepatotoxicity or hormonal effects associated with oral ketoconazole. It is safe for long-term use in seborrheic dermatitis and does not require liver monitoring or hormonal assessment. The adverse effects her father experienced were related to systemic exposure from oral administration. Topical ketoconazole is safe in women of reproductive age and the standard treatment duration is ongoing as needed, not just 3 days.

Frequently asked questions

How does ketoconazole work?

Ketoconazole inhibits the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for converting lanosterol to ergosterol, a critical component of fungal cell membranes. By blocking ergosterol synthesis, ketoconazole disrupts membrane integrity and permeability, leading to fungal cell death. It also inhibits mammalian CYP3A4 enzymes, causing significant drug interactions.

What are the side effects of ketoconazole?

Systemic ketoconazole's most serious side effect is hepatotoxicity, which can progress to liver failure. Endocrine effects include gynecomastia, decreased libido, menstrual irregularities, and adrenal insufficiency due to inhibition of steroid hormone synthesis. Gastrointestinal symptoms like nausea and abdominal pain are common. Numerous drug interactions occur due to potent CYP3A4 inhibition. Topical ketoconazole is generally well-tolerated with only local irritation.

Is ketoconazole safe for systemic use?

Systemic ketoconazole is considered unsafe for routine use and carries a black box warning due to hepatotoxicity, QT prolongation, and serious drug interactions. It has been largely replaced by safer azole antifungals like fluconazole and itraconazole for systemic infections. Oral ketoconazole is now reserved only for situations where alternative therapies are unavailable or ineffective, and requires close hepatic monitoring. Topical ketoconazole remains safe and widely used.

Why does ketoconazole cause gynecomastia?

Ketoconazole inhibits testosterone synthesis by blocking 17α-hydroxylase and 17,20-lyase enzymes in the testes and adrenal glands, reducing androgen levels. This leads to a decreased testosterone-to-estrogen ratio, with relatively increased estrogen activity. The hormonal imbalance stimulates breast tissue growth, resulting in gynecomastia in men receiving systemic ketoconazole therapy.

Ketoconazole vs fluconazole — what is the difference?

Ketoconazole and fluconazole are both azole antifungals but differ significantly. Ketoconazole is an imidazole with poor CNS penetration, significant hepatotoxicity, and potent CYP3A4 inhibition causing numerous drug interactions. Fluconazole is a triazole with excellent CNS penetration, better safety profile, less hepatotoxicity, and fewer drug interactions. Fluconazole has largely replaced systemic ketoconazole due to superior safety, though topical ketoconazole remains widely used.

Conditions it is used for

Tinea corporisTinea crurisTinea pedisTinea versicolorSeborrheic dermatitisCutaneous candidiasisDandruffCushing syndrome
FluconazoleItraconazoleVoriconazolePosaconazoleMiconazoleClotrimazoleTerbinafineGriseofulvin

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: D01AC08WHO ATC/DDD index: G01AF11

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.